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In 2012, the US Preventive Services Task Force (USPSTF), a panel of doctors and 
epidemiologists appointed by the US 
Department of Health and Human Services, 
recommended against prostate-specific 
antigen (PSA) screening for prostate cancer.1 
Its advice arose from randomised clinical 
trial data suggesting that many biopsies 
resulted in men being diagnosed and treated 
for low-grade prostate cancer that did not 
warrant treatment. Given their advanced age 
and comorbidity, the men were much more 
likely to die of causes other than prostate 
cancer. Furthermore, aggressive treatment led 
to substantial adverse effects that negatively 
impacted the patients’ quality of life. So, to 
avoid unnecessary biopsies and treatment, 
the USPSTF recommended abandoning  
PSA screening. In the last year, an advisory 
body in Canada, the Canadian Task Force  
on Preventative Health Care, has made a 
similar recommendation following a similar 
line of reasoning.2
WHAT DO PATIENTS THINK?
The thought of harbouring a treatable 
disease is intolerably stressful for some 
men. Destroying the offending organ and 
the cancer it contains is consistent with 
the ‘take action’ American psyche. There is 
no getting around the fact that living well 
with cancer, inconsequential or otherwise, 
does not compute as logical or reasonable 
for many men.
We believe, however, that the USPSTF did not 
consider the nuances of a situation where 
patients’ beliefs are not so rigid. How patients 
view prostate cancer can change and we 
believe will change, but not by following the 
position espoused by the USPSTF.
Admittedly there has been some decrease 
in the number of biopsies performed in the 
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USA since the USPSTF released its report.3 
Predictably though, that is associated with 
proportionately more men being diagnosed 
with intermediate- or high-risk cancer.4
It is not surprising then that the USPSTF 
position has led to a major outcry from 
many urologists in the USA and elsewhere,5 
who found it too rigid and absolute. Indeed 
many patients, who had been treated for 
prostate cancer, joined the protest arguing 
that they might have died of prostate 
cancer had it not been detected in time 
via the PSA test.6 This highly polarised 
debate has left many men wondering and 
worrying whether they should or should 
not get a PSA test.
WHAT TO SAY IF ASKED
So what should we in the prostate cancer 
community say when asked, ‘Should I 
get a PSA test?’ We would say, ‘Yes, you 
should get tested’, but a simple ‘yes’ or 
‘no’ answer does not solve the difficult 
problem many of the men will face should 
they be diagnosed with low-grade disease 
following confirmatory biopsy. What has 
not been resolved is how to best protect 
the men from a lethal cancer, while 
concurrently minimising their distress from 
a positive cancer diagnosis when their 
cancer is indolent and does not require 
prompt treatment.
If that is our goal, and we believe it should 
be, then we should proffer some counter-
questions: ‘Can you live comfortably 
knowing that you have a low-grade cancer, 
but are very likely better off not receiving 
therapy? And, if aggressive cancer is found, 
would you pursue treatment options?’ 
These are the relevant questions that get 
at the psychological core of the ‘test’ or 
‘not test’ PSA controversy. Such questions 
have led to extensive discussion about the 
challenges in educating patients so they 
have the necessary information to make an 
informed decision about PSA screening.7
In some ways, these questions have 
already been answered. And they bring 
to the surface a psychological issue not 
addressed in the epidemiology-driven 
recommendations from the USPSTF. 
Simply stated, the USPSTF did not consider 
the adaptability of men diagnosed with 
prostate cancer. The issues we should 
consider are discussed below.
Life expectancy
Because of improving healthcare — vaccines, 
antibiotics, good public sanitation — male 
life expectancy has increased greatly since 
prostate cancer was first identified some 
160 years ago. According to the SEER Stat 
Fact Sheet (http://seer.cancer.gov/statfacts/
html/prost.html), the median age of 
prostate cancer diagnosis in the USA now 
is 66 years, and for prostate cancer death, 
80 years. Furthermore, there has been 
a striking decrease in prostate-cancer-
specific mortality in recent decades.8 If 
not ‘cured’, prostate cancer can now be 
controlled in many cases along the lines of 
other chronic diseases, such as diabetes or 
high blood pressure. 
Living with untreated cancer is not easy 
This is evidenced by the fact that many 
men on active surveillance (AS) withdraw 
within three years.9 Disease progression 
is one driving factor for abandoning 
AS, but anxiety is clearly another factor 
for why some men elect for treatment. 
However, there is every reason to believe 
that this mindset can change. As noted 
in Davison and Goldenberg,10 physician 
recommendation is the strongest factor 
for men to elect AS. The case for AS when 
presented to patients can be bolstered by 
informing patients about discussion among 
academic pathologists as to whether a 
Gleason ≤6 diagnosis should even be 
called ‘cancer’.11 As more men understand 
that Gleason ≤6 prostate cancer has little, 
if any, metastatic capability, more men 
should be willing to elect for and comply 
with AS.
The USPSTF understood, of course, the 
indolent nature of Gleason ≤6 prostate 
cancer. However, they did not explore the 
fact that the public’s understanding of the 
benign nature of low-risk prostate cancer 
can also change.
In response to the USPSTF, many 
organisations have called for doctors 
and patients to discuss the pros and 
cons of screening. Vickers et al7 provides 
a decision-making tool, acknowledging 
the need to balance evidence-based data 
against the risk of overloading the patient 
with too much information. One thing  
they do not consider, however, is the 
relative experience that the patients have 
had with other patients on AS protocols.  
This, we believe, is an important and 
under-appreciated variable.
Identifying the inherently anxious
The raw fact is that some men, who are 
on AS, experience substantial anxiety, 
especially younger patients or those who 
have been diagnosed for a long time.12 
Clearly, there are those who abandon AS 
because of anxiety and seek potentially 
curative treatments.13 They do this, not 
because the disease has necessarily 
changed to a more aggressive form, but 
because they simply can’t dispel the 
intrusive thought that they have cancer. 
The men who find AS psychologically 
intolerable, however, appear to be an 
inherently anxious minority.14 According 
to Anderson et al,15 a small percentage of 
patients on AS had clinically significant 
anxiety that could be related to prostate 
cancer itself (12.8%), fear of recurrence 
(8.1%) or PSA testing (1.2%). In another 
study,10 19% of patients reported moderate 
‘ There is no getting around the fact that living well with 
cancer, inconsequential or 
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to severe anxiety while on AS. These 
relatively low numbers appear to reflect 
a subset of men, whose innate anxiety 
level is probably too high to make them 
good candidates for AS, regardless of their 
Gleason score. Indeed, one study indicates 
that patients with neurotic personality 
have unfavourable anxiety and distress 
scores while on AS.16 As such, we need 
good, simple assessment instruments 
that can help identify such individuals 
upfront in the clinical setting. Potentially, 
such instruments may also help avoid 
overdiagnosis and overtreatment in  
men who have anxiety issues. Knowing 
their propensity to catastrophise might 
save physicians from spending protracted 
amounts of time convincing such patients 
to go on AS, only to have them debilitated 
by anxiety and prematurely abandon  
the protocol.
Excluding that minority of men, we predict 
that as AS becomes a more common 
‘standard of care’, more men diagnosed 
with low-risk prostate cancer will elect to 
stay on AS for a longer time. The anxiety 
associated with being diagnosed with 
cancer, and not having it treated, should 
progressively decrease as each new  
patient becomes aware of the number  
of other patients who are already on an  
AS protocol. 
Individualising the approach
Right now the American Cancer Society 
estimates some 220 000 new prostate 
cancer cases in 2015 with around  
27 500 deaths due to prostate cancer. As 
USPSTF noted, PSA screening will lead to 
more men being diagnosed with indolent 
cancer. But as more men become aware 
that in most cases prostate cancer – 
diagnosed in the modern PSA era – is 
slow-growing and non-life-threatening, 
AS itself will increasingly be acceptable 
and tolerated. 
Although currently available nomograms 
to distinguish insignificant from 
significant prostate cancer are not 
ideal,17 they are improving. With better 
imaging (ie state of the art MRI) and 
new biomarkers, uro-oncologists are 
increasingly in a position to advise men 
with increasing confidence about whether 
they should or should not remain on an 
AS protocol. Using ‘smart’ PSA screening, 
doctors can establish individualised 
schedules for PSA testing, ie this 
recognises that not every man needs  
an annual PSA test, not every rise in  
PSA needs to lead to a biopsy (reducing 
the risk of septic complications for 
multiple biopsies), and not every patient 
with a positive biopsy needs prompt 
treatment. There is no question, though, 
that with more patients accepting AS 
protocols, potentially lethal cancer will  
be captured along the way and treated 
when still curable. 
Coping confidence
A recent paper identified that what 
mattered most when it came to living 
comfortably with AS is patients’ ‘coping 
confidence’.18 Other psychological factors 
that one might suspect would be relevant, 
such as the ability to relax, were not nearly 
as important. Although the psychological 
adjustment to AS was beyond the purview 
of the USPSTF, from a public health 
perspective what is critical is the fact that 
‘coping confidence’ is not a fixed trait, but 
a variable state. One’s coping confidence 
in dealing with any potentially stressful 
situation, such as living with prostate 
cancer, is likely to be low if one’s most 
dominant experience with the disease 
is the death of close friends or relatives. 
Conversely, as the number of men dying of 
prostate cancer goes down and the number 
on AS goes up, more men will be confident 
that they can cope with a prostate cancer 
diagnosis. There is already a hint that this 
is going on in some cancer centres. For 
example, at one site in Michigan some 50% 
of patients with low Gleason scores are 
now going on AS.19 
Coping with AS, and living with cancer 
in general, typically involves not just 
a challenge for patients but also other 
family members.20 It is noteworthy that 
interventions to enhance coping not just 
for patients, but also their partners, are 
now being designed and evaluated.21
CONCLUSION
When it comes to health risks, humans 
are Bayesian organisms22 and our anxiety 
levels are always adjusted by changes in 
the frequency of associations that can 
raise or lower anxiety. The USPSTF did not 
consider the fact that tolerance for AS 
should increase in a feedback fashion as 
more men embark on AS protocols. 
So, when we are asked ‘Should I get a PSA 
test?’, our answer should acknowledge 
the fluid nature of cancer fear. ‘Yes’, we 
should say — ‘You should get tested’.  
But also tell them that they may get 
diagnosed with low-risk disease that 
may not warrant any treatment for years, 
if at all. Ask them how many men they 
know right now, who are on AS? Do they 
know that the numbers of men on AS is 
rising while the number of men dying 
of prostate cancer is falling? Tell them, 
though, that because some men still die 
of this disease, it is best to know where 
they stand and have a PSA test.
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‘ As more men become aware that in most cases prostate cancer – diagnosed in the modern PSA era – is slow-
growing and non-life-threatening, active surveillance will 
increasingly be acceptable and tolerated’
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